The risk of arachnoiditis from experimental nonionic contrast media.
Victor M. Haughton, Khang‐Cheng Ho
Abstract
Victor M. Haughton, Khang‐Cheng Ho
Abstract
Aqueous myelographic contrast media are needed that are less expensive and better tolerated than metrizamide. This study compares two new, nonionic aqueous contrast media, ioglunide and iopamidol, with two previously developed contrast media, metrizamide and iocarmate. Myelography was performed with one of the contrast media in monkeys; four weeks later the degree of arachnoid fibrosis was determined in each animal by myelographic and histologic studies of the dural sac. Iopamidol, ioglunide, and metrizamide produced no more arachnoid changes than were found in the control animals. Iocarmate produced moderate to severe arachnoiditis.
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Aqueous myelographic contrast media are needed that are less expensive and better tolerated than metrizamide. This study compares two new, nonionic aqueous contrast media, ioglunide and iopamidol, with two previously developed contrast media, metrizamide and iocarmate. Myelography was performed with one of the contrast media in monkeys; four weeks later the degree of arachnoid fibrosis was determined in each animal by myelographic and histologic studies of the dural sac. Iopamidol, ioglunide, and metrizamide produced no more arachnoid changes than were found in the control animals. Iocarmate produced moderate to severe arachnoiditis.
Key concepts: Metrizamide, Iopamidol, Arachnoiditis, Medicine, Myelography, Contrast medium, Contrast (vision), Intrathecal